arXiv:2605.16356v1 Announce Type: new
Abstract: Exhaled breath condensate (EBC) contains volatile metabolites and is promising for non-invasive disease diagnosis, but after decades of research spanning over 100 biomarkers and 10 diseases, no EBC-based test has reached clinical use. The measurement variability that can span orders of magnitude, far exceeding the clinically required 10%, has long been attributed to biological factors. Here, we reveal a fundamentally different origin: the collected microdroplets themselves fail to retain volatile biomarkers. By isolating volatile co-condensation and transient evaporation from biological interference, we show that EBC microdroplets smaller than 100 mum lose clinically significant volatile content within a single breath cycle. This challenges the implicit assumption underlying decades of EBC research, that condensate faithfully reflects airway lining fluid. We develop and validate a physics-based model that predicts this loss across disease-relevant biomarkers and establishes the conditions for reliable EBC sampling. This work reframes EBC variability as a solvable engineering problem rather than an inherent biological limitation.
Digital health tools and point solutions—pitfalls in population health program measurement
Digital health tools are generally poorly regulated and often lack strong research evidence, posing challenges for purchasers of point solutions such as employer groups and